Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration.

Rosalia Giustolisi,Nicoletta Fantozzi,Mariateresa Staltari,Jessica Marchiori,Olga Mastrangelo,Roberta Marcucci,Federica Mirra,Paola Mazzotta,Corrado Balacco Gabrieli

Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration.

2011

Rosalia Giustolisi
Nicoletta Fantozzi
Mariateresa Staltari
Jessica Marchiori
Olga Mastrangelo
Roberta Marcucci
Federica Mirra
Paola Mazzotta
Corrado Balacco Gabrieli

Purpose: To compare same-day combined therapy of photodynamic therapy with verteporfin (PDT-V) and intravitreal ranibizumab versus monotherapy with ranibizumab for the treatment of choroidal neovascularization.

Keywords:

Ranibizumab
Macular degeneration
Verteporfin
Photodynamic therapy
Choroidal neovascularization
Surgery
Medicine
Endophthalmitis
Retinal detachment
Visual acuity
Ophthalmology
Ocular hypertension

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations